Almstead Neil Gregory 4
4 · PTC THERAPEUTICS, INC. · Filed Jul 13, 2026
Research Summary
AI-generated summary of this filing
PTC Therapeutics CTO Neil Almstead Exercises Options, Sells Shares
What Happened
Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics (PTCT), exercised 2,464 stock options and immediately sold the resulting 2,464 shares on July 9, 2026. The options were exercised at $46.54 per share (total cash cost $114,675), and the shares were sold in the open market at a weighted average price of $90.25 per share for total proceeds of approximately $222,376. The filing shows the option conversion/disposition entry at $0.00, reflecting the conversion of the derivative into shares and subsequent sale.
Key Details
- Transaction date: July 9, 2026.
- Exercise: 2,464 shares at $46.54 each = $114,675 (Form 4 code M).
- Sale: 2,464 shares at weighted avg $90.25 each = $222,376 (Form 4 code S). Sales executed at prices between $90.00 and $90.70 (see footnote F2).
- Plan/authorization: Sales were effected pursuant to a written Rule 10b5-1 trading plan adopted Nov 11, 2025 (footnote F1).
- Option grant/vesting: Option granted Jan 3, 2025; vests 25% on Jan 3, 2026 and 6.25% each quarter thereafter (footnote F3).
- Shares owned after transaction: Not disclosed in the provided filing.
- Filing timeliness: Reported on July 13, 2026; filed within the SEC two-business-day reporting window for the July 9 transaction.
Context
This was an exercise of vested options followed by an immediate open-market sale (commonly a cashless exercise). The use of a pre-established Rule 10b5-1 plan indicates the sale was executed under a pre-set trading arrangement rather than an ad-hoc decision; footnote F2 indicates multiple trades produced the reported weighted average sale price.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-07-09$46.54/sh+2,464$114,675→ 62,763 total - Sale
Common Stock
[F1][F2]2026-07-09$90.25/sh−2,464$222,376→ 60,299 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]2026-07-09−2,464→ 45,036 totalExercise: $46.54Exp: 2035-01-02→ Common Stock (2,464 underlying)
- 2,899(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
- [F2]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F3]This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.